Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1994 1
1997 1
1998 1
2002 1
2004 1
2006 1
2007 2
2008 5
2009 4
2010 1
2011 2
2012 3
2013 3
2014 1
2015 6
2016 1
2017 4
2018 5
2019 2
2020 5
2021 7
2022 10
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for daily rajput
Your search for Daizy Rajput retrieved no results
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O; ONWARDS 1 Trial Investigators. Rosenstock J, et al. N Engl J Med. 2023 Jul 27;389(4):297-308. doi: 10.1056/NEJMoa2303208. Epub 2023 Jun 24. N Engl J Med. 2023. PMID: 37356066 Clinical Trial.
Participants were randomly assigned in a 1:1 ratio to receive once-weekly insulin icodec or once-daily insulin glargine U100. The primary end point was the change in the glycated hemoglobin level from baseline to week 52; the confirmatory secondary end point was the percen …
Participants were randomly assigned in a 1:1 ratio to receive once-weekly insulin icodec or once-daily insulin glargine U100. The pri …
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Velazquez EJ, et al. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. N Engl J Med. 2019. PMID: 30415601 Clinical Trial.
After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged …
After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 …
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical wors …
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical o …
The mechanism of nanoparticle toxicity to cyanobacteria.
Kumar M, Sabu S, Sangela V, Meena M, Rajput VD, Minkina T, Vinayak V, Harish. Kumar M, et al. Arch Microbiol. 2022 Dec 16;205(1):30. doi: 10.1007/s00203-022-03370-2. Arch Microbiol. 2022. PMID: 36525087 Review.
Exposure to nanoparticles in the environment is unavoidable as nanomaterials are used more prevalent in our daily lives, and as a result, nanotoxicity research is gaining traction. ...
Exposure to nanoparticles in the environment is unavoidable as nanomaterials are used more prevalent in our daily lives, and as a res …
SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.
Zolfaghari MA, Ghadiri Moghaddam F, Rajput S, Karimi A, Naghi Vishteh M, Mahmoodpoor A, Dolati S, Yousefi M. Zolfaghari MA, et al. Cell Biol Int. 2022 Dec;46(12):2009-2017. doi: 10.1002/cbin.11903. Epub 2022 Sep 1. Cell Biol Int. 2022. PMID: 36047303 Free PMC article. Review.
After more than 2 years of the coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome coronavirus 2, several questions have remained unanswered that affected our daily lives. Although substantial vaccine development could resist this challenge, emerg …
After more than 2 years of the coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome coronavirus 2, several question …
Novel Dynamic Prediction of Daily Patient Discharge in Acute and Critical Care.
Lajevardi-Khosh A, Jalali A, Rajput KS, Selvaraj N. Lajevardi-Khosh A, et al. Annu Int Conf IEEE Eng Med Biol Soc. 2021 Nov;2021:2347-2352. doi: 10.1109/EMBC46164.2021.9630453. Annu Int Conf IEEE Eng Med Biol Soc. 2021. PMID: 34891754
This paper presents a novel algorithm for the prediction of likelihood of patient discharge within the next 24 or 48 hours from acute or critical care environments on a daily basis. Continuous patient monitoring and health data obtained from acute hospital at home environm …
This paper presents a novel algorithm for the prediction of likelihood of patient discharge within the next 24 or 48 hours from acute or cri …
Emerging applications and prospects of NFκB decoy oligodeoxynucleotides in managing respiratory diseases.
Datsyuk JK, Paudel KR, Rajput R, Kokkinis S, El Sherkawi T, Singh SK, Gupta G, Chellappan DK, Yeung S, Hansbro PM, Oliver BGG, Santos HA, Dua K, De Rubis G. Datsyuk JK, et al. Chem Biol Interact. 2023 Nov 1;385:110737. doi: 10.1016/j.cbi.2023.110737. Epub 2023 Sep 27. Chem Biol Interact. 2023. PMID: 37774998 Review.
Currently, there are only preventative treatments in the form of mono- or multiple-drug therapy available to patients who need to utilize it daily. Hence, throughout the years there has been a substantial amount of research in understanding what causes inflammation in the …
Currently, there are only preventative treatments in the form of mono- or multiple-drug therapy available to patients who need to utilize it …
Multiomics and optobiotechnological approaches for the development of microalgal strain for production of aviation biofuel and biorefinery.
Kumar A, Baldia A, Rajput D, Kateriya S, Babu V, Dubey KK. Kumar A, et al. Bioresour Technol. 2023 Feb;369:128457. doi: 10.1016/j.biortech.2022.128457. Epub 2022 Dec 9. Bioresour Technol. 2023. PMID: 36503094 Review.
Demand and consumption of fossil fuels is increasing daily, and oil reserves are depleting. Technological developments are required towards developing sustainable renewable energy sources and microalgae are emerging as a potential candidate for various application-driven r …
Demand and consumption of fossil fuels is increasing daily, and oil reserves are depleting. Technological developments are required t …
Assessment of data intelligence algorithms in modeling daily reference evapotranspiration under input data limitation scenarios in semi-arid climatic condition.
Rajput J, Singh M, Lal K, Khanna M, Sarangi A, Mukherjee J, Singh S. Rajput J, et al. Water Sci Technol. 2023 May;87(10):2504-2528. doi: 10.2166/wst.2023.137. Water Sci Technol. 2023. PMID: 37257106
The efficacy of the constructed models was assessed against the Penman-Monteith (PM56) model estimated daily ET(o). Results revealed the under full and limited dataset conditions, XGBoost Ensemble Tree gave the best results for daily ET(o) modeling during the model …
The efficacy of the constructed models was assessed against the Penman-Monteith (PM56) model estimated daily ET(o). Results revealed …
Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions.
Sharma AK, Rani E, Waheed A, Rajput SK. Sharma AK, et al. J Epilepsy Res. 2015 Jun 30;5(1):1-8. doi: 10.14581/jer.15001. eCollection 2015 Jun. J Epilepsy Res. 2015. PMID: 26157666 Free PMC article. Review.
The failure to achieve seizure control with the first or second drug trial of an anticonvulsant medication given at the appropriate daily dosage is termed as pharmacoresistance, despite the fact that these drugs possess different modes of action. ...
The failure to achieve seizure control with the first or second drug trial of an anticonvulsant medication given at the appropriate daily …
72 results